Data released by the FDA show that Revolution Medicine’s newly approved pancreatic cancer drug underperformed in a large subgroup of patients, but analysts say the biotech still has a clear winner.

Original title: “RevMed's Rasonque gets a subtype data asterisk, but analysts remain bullish”

The centerpiece of Bristol Myers Squibb’s 2024 RayzeBio buy has read out, hitting the primary endpoint in a late-stage tumor trial.

Original title: “BMS’ $4.1B RayzeBio bet delivers Phase 3 radiopharma win”

Merck is the most vulnerable to generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.

Original title: “Pharma’s $500B patent problem will come in waves — not as a cliff”

Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.

Original title: “Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data”

Starting next year, GSK plans to demolish existing buildings and construct new facilities to support clinical and commercial supply. The investment will create more than 300 new jobs over the next five years, Pennsylvania state officials said.

Original title: “GSK pledges $800M to add biologics production capabilities in Pennsylvania”

Collaboration to expand personalised cancer immunotherapy

Original title: “NHS Blood and Transplant partners with Northwest Biotherapeutics”

CDMO-sponsor relationships have shifted from transactional outsourcing to strategic collaboration built on shared risk, regulatory fluency and technical insight. As rising compliance pressure and geopolitical volatility reshape manufacturing, partners like Rose BioSolutions argue that true value now comes from challenging assumptions, anticipating hurdles and protecting programs before problems surface.

Original title: “Successful CDMO partnerships hinge on honest—and sometimes critical—support”

The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a much-needed cash infusion and TCGX started a China-focused fund.

Original title: “FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts”

The latest installment in BioPharma Dive’s data visualization series features a look at the factors pressuring biotech stocks of late and the frenetic pace of startup buyouts this year.

Original title: “This week in charts: What’s driving biotech’s recent pullback?”

With an internal non-opioid program nearing approval, Viatris is picking up Pacira BioSciences for a broader pain portfolio and the associated commercial infrastructure.

Original title: “Viatris inks $1.65B Pacira buyout to build non-opioid pain therapy business”

The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to Korea National Institute of Health, located in Cheongju-si, Chungcheongbuk-do, South Korea to practice the invention embodied in the patent application listed in the Supplementary Information section of this notice.

Original title: “Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Antibody Specifically Binding to Severe Fever With Thrombocytopenia Syndrome Virus Antigen and Use Thereof”